Trisomy 14 as a Sole Chromosome Abnormality Is Associated with Older Age, a Heterogenous Group of Myeloid Neoplasms with Dysplasia, and a Wide Spectrum of Disease Progression

Table 1

Clinical, morphologic, and cytogenetic characteristics of patients with myelodysplastic syndrome and isolated trisomy 14.

Age (Y)	Sex	WBC (10^9/L)	Hb (g/dL)	Platelet (10^9/L)	WHO classification	Karyotype	Cellularity (%)	Blast (%)	Trilineage dysplasia	IPSS score
79	M	4.2	10.1	79	RAEB-1	47, XY, +14 [3]/46,XY [14]	90	8	Yes	1.0
79	M	1.6	9.2	75	RAEB-2	47, XY, +14 [8]/46,XY [12]*	15	18	Yes	2.5
75	F	4.5	11.2	38	RAEB-1	47, XX, +14 [3]/46,XX [14]*	65	13	Yes	2.0
70	M	3.4	8.1	23	RAEB-2	46, XX, i(14)(q10) [8]	90	13	Yes	2.5
73	M	3.9	10.0	351	RARS	46, X, -Y,+14 [3]/45, X, -Y [2]/ 46, XY [15]*	35	4	Yes	1.0
63	M	8.8	10.8	465	RARS	46, XY, i(14)(q10) [5]/46, XY [15]*	60	2	Yes	0.5
68	M	6.0	8.5	156	RCMD	46, XY, i(14)(q10) [16]	95	1	Yes	0.5

*Diploid karyotype at time of initial diagnosis.
Y: years; M: male; F: female; WBC: white blood cell; Hb: hemoglobin; RAEB: refractory anemia with excess blasts; RARS: refractory anemia with ring sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; IPSS: international prognostic scoring system.